Detalles de la búsqueda
1.
Early intervention and disease modification in atopic dermatitis-the current state of the field and barriers to progress.
J Eur Acad Dermatol Venereol
; 38(4): 665-672, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38063244
2.
Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc analysis of JADE REGIMEN.
J Eur Acad Dermatol Venereol
; 2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38752592
3.
Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials.
J Eur Acad Dermatol Venereol
; 37(9): 1863-1870, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37184290
4.
Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics.
J Eur Acad Dermatol Venereol
; 37(9): 1871-1880, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37247226
5.
Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.
Br J Dermatol
; 186(3): 453-465, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34637142
6.
Facial erythema in patients with atopic dermatitis treated with Dupilumab - a descriptive study of morphology and Aetiology.
J Eur Acad Dermatol Venereol
; 36(11): 2140-2152, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35695074
7.
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Br J Dermatol
; 184(3): 437-449, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33000465
8.
Measurement properties of patient-reported outcome measures for eczema control: a systematic review.
J Eur Acad Dermatol Venereol
; 35(10): 1987-1993, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33977561
9.
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.
J Eur Acad Dermatol Venereol
; 35(2): 476-485, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32926462
10.
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.
J Eur Acad Dermatol Venereol
; 35(2): 464-475, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32893393
11.
Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
Br J Dermatol
; 182(1): 104-111, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30972740
12.
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis.
Br J Dermatol
; 182(6): e186-e209, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32476149
13.
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
Br J Dermatol
; 182(5): 1120-1135, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31407311
14.
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Br J Dermatol
; 183(2): 242-255, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31995838
15.
The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada.
J Eur Acad Dermatol Venereol
; 34(5): 1026-1036, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31587373
16.
Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults.
Br J Dermatol
; 181(3): 554-565, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30838645
17.
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
Br J Dermatol
; 181(1): 80-87, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30791102
18.
Conjunctivitis in dupilumab clinical trials.
Br J Dermatol
; 181(3): 459-473, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30851191
19.
A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants.
J Eur Acad Dermatol Venereol
; 33(11): 2087-2094, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31287580
20.
Harmonizing body surface area assessments between the Eczema Area and Severity Index, SCORing Atopic Dermatitis, and handprint methods utilizing one shared measurement-A proposal to improve efficiency and reduce error in atopic dermatitis trials.
J Eur Acad Dermatol Venereol
; 2024 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38385652